Study identification

EU PAS number

EUPAS16875

Study ID

26154

Official title and acronym

Investigating the possible role of BLood eosinophil counts in guiding ANti-inflammatory treatment of COPD exAcerbations (BLANCA)

DARWIN EU® study

No

Study countries

United Kingdom

Study description

A matched historical database study among patients with COPD in the UK will be conducted. The index date is defined as the date of any exacerbation with a blood eosinophil count measurement available on the same day and with a one-year baseline and at least 6 weeks post index date. A dataset of unique patients from the Optimum Patient Care Research Database (OPCRD) will be used for analyses. Moreover, the Clinical Practice Research Datalink (CPRD) will be used to increase the number of available patients fitting the inclusion and exclusion criteria. The dataset from both the sources will be combined and duplicate records will be removed. A combined dataset of unique patients will be used for all the analyses. The study population will consist of patients with a COPD diagnostic Read code, with blood eosinophil counts recorded on an exacerbation date with no OCS and antibiotic use during the 2 weeks before the event and registered at general practices providing data to OPCRD (or CPRD) across the United Kingdom.

Study status

Finalised
Research institutions and networks

Institutions

Contact details

David Price

Primary lead investigator

Study timelines

Date when funding contract was signed

Planned:
Actual:

Study start date

Planned:
Actual:

Data analysis start date

Planned:
Actual:

Date of final study report

Planned:
Actual:
Sources of funding
Pharmaceutical company and other private sector 

More details on funding

AstraZeneca
Regulatory

Was the study required by a regulatory body?

No

Is the study required by a Risk Management Plan (RMP)?

Not applicable